PEAK6 Investments’s Aldeyra Therapeutics ALDX Stock Holding History

PEAK6 Investments’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,500	Closed	-$46.1K	–	4005
2023 Q2	$46.1K	Sell	5,500 -5,500	-50%	-$54.2K	﹤0.01%	3458
2023 Q1	$109K	Buy	+11,000	New	+$77.8K	﹤0.01%	3474
2022 Q3	–	Sell	-5,500	Closed	-$46.1K	–	4874
2022 Q2	$46.1K	Buy	+5,500	New	+$18.9K	﹤0.01%	5539

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

PEAK6 Investments's ALDX Position: Q3 2023 in Review

PEAK6 Investments sold out of Aldeyra Therapeutics (ALDX) in Q3 2023, closing a stake of 5,500 shares — an estimated $46.1K sold.

PEAK6 Investments first reported a position in ALDX in Q2 2022 and held it in 3 quarters. The position peaked at $109K in Q1 2023. 120 funds tracked by Wall St. Rank hold ALDX as of Q3 2023.

PEAK6 Investments reported no remaining Aldeyra Therapeutics position as of Q3 2023 after selling out during the quarter.
PEAK6 Investments sold 5,500 Aldeyra Therapeutics shares in Q3 2023, an estimated $46.1K.
PEAK6 Investments first reported a position in Aldeyra Therapeutics in Q2 2022 and held it in 3 quarters.
PEAK6 Investments's Aldeyra Therapeutics position peaked at $109K in Q1 2023.
120 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2023.

Based on PEAK6 Investments's 13F filing for Q3 2023, filed 13 Nov 2023.